19.11.2019

Official Journal of the European Union

C 392/1

Non-opposition to a notified concentration

(Case M.9548 — Apollo Capital Management/Covivio/Hilton Kilmainham)

(Text with EEA relevance)

(2019/C 392/01)

On 8 November 2019, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

—	in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

—	in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32019M9548. EUR-Lex is the online access to European law.

(1) OJ L 24, 29.1.2004, p. 1.

19.11.2019

Official Journal of the European Union

C 392/2

Non-opposition to a notified concentration

(Case M.9570 — Bridgepoint/Latour/Primonial)

(Text with EEA relevance)

(2019/C 392/02)

On 11 November 2019, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in French and will be made public after it is cleared of any business secrets it may contain. It will be available:

—	in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

—	in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32019M9570. EUR-Lex is the online access to European law.

(1) OJ L 24, 29.1.2004, p. 1.

19.11.2019

Official Journal of the European Union

C 392/3

Non-opposition to a notified concentration

(Case M.9509 — Warburg Pincus/CDPQ/Allied Universal)

(Text with EEA relevance)

(2019/C 392/03)

On 11 November 2019, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

—	in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

—	in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32019M9509. EUR-Lex is the online access to European law.

(1) OJ L 24, 29.1.2004, p. 1.

19.11.2019

Official Journal of the European Union

C 392/4

Notice for the attention of the persons subject to the restrictive measures provided for in Council Decision 2011/72/CFSP and Council Regulation (EU) No 101/2011 concerning restrictive measures directed against certain persons, entities and bodies in view of the situation in Tunisia

(2019/C 392/04)

The following information is brought to the attention of the persons that appear in the Annex to Council Decision 2011/72/CFSP (1), and in Annex I to Council Regulation (EU) No 101/2011 (2), concerning restrictive measures directed against certain persons, entities and bodies in view of the situation in Tunisia.

The Council intends to renew the restrictive measures provided for in Decision 2011/72/CFSP. The Council holds on its file new elements concerning all persons listed in the Annex to Decision 2011/72/CFSP and in Annex I to Regulation (EU) No 101/2011.The persons concerned are hereby informed that they may submit a request to the Council to obtain the information that relates to them, before 25 November 2019, to the following address:

Council of the European Union

General Secretariat

RELEX.1.C

Rue de la Loi/Wetstraat 175

1048 Bruxelles/Brussel

BELGIQUE/BELGIË

Email: sanctions@consilium.europa.eu

Any observations received will be taken into account for the purpose of the Council’s periodic review, in accordance with Article 5 of Decision 2011/72/CFSP and Article 12(4) of Regulation (EU) No 101/2011.

(1) OJ L 28, 2.2.2011, p. 62.

(2) OJ L 31, 5.2.2011, p. 1.

19.11.2019

Official Journal of the European Union

C 392/5

Notice for the attention of the data subjects to whom the restrictive measures provided for in Council Decision 2011/72/CFSP and Council Regulation (EU) No 101/2011 concerning restrictive measures directed against certain persons, entities and bodies in view of the situation in Tunisia apply

(2019/C 392/05)

The attention of data subjects is drawn to the following information in accordance with Article 16 of Regulation (EU) 2018/1725 of the European Parliament and of the Council (1).

The legal basis for this processing operation are Council Decision (CFSP) 2011/72/CFSP (2) and Council Regulation (EU) No 101/2011 (3).

The controller of this processing operation is the Department RELEX.1.C in the Directorate-General for Foreign Affairs, Enlargement and Civil Protection — RELEX of the General Secretariat of the Council (GSC), that can be contacted at:

Council of the European Union

General Secretariat

RELEX.1.C

Rue de la Loi/Wetstraat 175

1048 Bruxelles/Brussel

BELGIQUE/BELGIË

Email: sanctions@consilium.europa.eu

The GSC’s Data Protection Officer can be contacted at:

Data Protection Officer

data.protection@consilium.europa.eu

The purpose of the processing operation is the establishment and updating of the list of persons subject to restrictive measures in accordance with Decision (CFSP) 2011/72/CFSP and Regulation (EU) No 101/2011.

The data subjects are the natural persons who fulfil the listing criteria as laid down in Decision (CFSP) 2011/72/CFSP and Regulation (EU) No 101/2011.

The personal data collected includes data necessary for the correct identification of the person concerned, the statement of reasons and any other data related thereto.

The personal data collected may be shared as necessary with the European External Action Service and the Commission.

Without prejudice to restrictions pursuant to Article 25 of Regulation (EU) 2018/1725, the exercise of the rights of the data subjects such as the right of access, as well as the rights to rectification or to object will be answered in accordance with Regulation (EU) 2018/1725.

Personal data will be retained for 5 years from the moment the data subject has been removed from the list of persons subject to the restrictive measures or the validity of the measure has expired, or for the duration of court proceedings in the event they had been started.

Without prejudice to any judicial, administrative or non-judicial remedy, data subjects may lodge a complaint with the European Data Protection Supervisor in accordance with Regulation (EU) 2018/1725 (edps@edps.europa.eu).

(1) OJ L 295, 21.11.2018, p. 39.

(2) OJ L 28, 2.2.2011, p. 62.

(3) OJ L 31, 5.2.2011, p. 1.

19.11.2019

Official Journal of the European Union

C 392/6

Euro exchange rates (1)

18 November 2019

(2019/C 392/06)

1 euro =

	Currency	Exchange rate
USD	US dollar	1,1061
JPY	Japanese yen	120,55
DKK	Danish krone	7,4726
GBP	Pound sterling	0,85330
SEK	Swedish krona	10,6603
CHF	Swiss franc	1,0960
ISK	Iceland króna	135,90
NOK	Norwegian krone	10,0860
BGN	Bulgarian lev	1,9558
CZK	Czech koruna	25,593
HUF	Hungarian forint	335,27
PLN	Polish zloty	4,2915
RON	Romanian leu	4,7744
TRY	Turkish lira	6,3316
AUD	Australian dollar	1,6242
CAD	Canadian dollar	1,4622
HKD	Hong Kong dollar	8,6593
NZD	New Zealand dollar	1,7275
SGD	Singapore dollar	1,5047
KRW	South Korean won	1 289,14
ZAR	South African rand	16,3463
CNY	Chinese yuan renminbi	7,7629
HRK	Croatian kuna	7,4400
IDR	Indonesian rupiah	15 588,27
MYR	Malaysian ringgit	4,5964
PHP	Philippine peso	56,081
RUB	Russian rouble	70,6242
THB	Thai baht	33,443
BRL	Brazilian real	4,6201
MXN	Mexican peso	21,2907
INR	Indian rupee	79,4260

(1) Source: reference exchange rate published by the ECB.

19.11.2019

Official Journal of the European Union

C 392/9

Prior notification of a concentration

(Case M.9639 — CDC/EDF/Dalkia Investissement)

Candidate case for simplified procedure

(Text with EEA relevance)

(2019/C 392/09)

On 11 November 2019, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).

This notification concerns the following undertakings:

—	Electricité de France (‘EDF’, France),

—	Caisse des dépôts et consignations (‘CDC’, France),

—	Dalkia Investissement SAS (‘Dalkia Investissement’, France), controlled by EDF.

EDF and CDC acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of Dalkia Investissement.

The concentration is accomplished by way of purchase of shares.

The business activities of the undertakings concerned are:

—	EDF and its subsidiaries are mainly active in the electricity sector, especially in the generation and wholesale of electricity, transportation and distribution of electricity in France and abroad. It is also active in the gas sector and in energy related services in France and abroad,

—	CDC is a French public institution with a special legal status, active in the management of private funds to which public authorities wish to provide special protection and in the financing of public-interest investment projects (transport, environment, transmission of electricity, etc.),

—	Dalkia Investissement is a holding company owning part of the shares of ELM SAS, which is responsible for the exploitation of the heat and cold networks of certain areas of the city of Lyon.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

Case M.9639 — CDC/EDF/Dalkia Investissement

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.

19.11.2019

Official Journal of the European Union

C 392/11

Prior notification of a concentration

(Case M.9343 — Hyundai Heavy Industries/Daewoo Shipbuilding & Marine Engineering)

(Text with EEA relevance)

(2019/C 392/10)

On 12 November 2019, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).

This notification concerns the following undertakings:

—	Hyundai Heavy Industries Co., Ltd. (‘HHI’) (Korea),

—	Daewoo Shipbuilding & Marine Engineering Co., Ltd. (‘DSME’) (Korea), controlled by the Korea Development Bank (‘KDB’).

HHI acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of DSME.

The concentration is accomplished by way of purchase of shares.

The business activities of the undertakings concerned are:

—	for HHI: a Korean company mainly active in the construction of commercial vessels, including oil tankers, containerships, liquefied natural gas (‘LNG’) carriers and liquefied petroleum gas (‘LPG’) carriers, military vessels, and offshore facilities and the production of marine engines,

—	for DSME: a Korean company mainly active in the construction of commercial vessels including oil tankers, containerships, liquefied natural gas (‘LNG’) carriers and liquefied petroleum gas (‘LPG’) carriers and offshore facilities.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.9343 — Hyundai Heavy Industries/Daewoo Shipbuilding & Marine Engineering.

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

19.11.2019

Official Journal of the European Union

C 392/12

Prior notification of a concentration

(Case M.9461 — AbbVie/Allergan)

(Text with EEA relevance)

(2019/C 392/11)

On 12 November 2019, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).

This notification concerns the following undertakings:

—	AbbVie Inc., (‘AbbVie’, United States),

—	Allergan plc (‘Allergan’, Ireland).

AbbVie acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Allergan.

The concentration is accomplished by way of purchase of shares.

The business activities of the undertakings concerned are:

—

AbbVie is a global pharmaceutical company listed on the New York Stock Exchange and headquartered in the United States. AbbVie is engaged in the development and commercialisation of innovative medicines in six main therapeutic areas: immunology (including autoimmune diseases), oncology, virology, neuroscience/central nervous system disorders, metabolic diseases and pain associated with endometriosis;

—

Allergan is a global pharmaceutical company listed on the New York Stock Exchange and headquartered in Ireland. Allergan is engaged in the development and commercialisation of medicines in four key therapeutic areas: medical aesthetics, eye care, neuroscience/central nervous system disorders and gastroenterology.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.9461 — AbbVie/Allergan

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

		ISSN 1977-091X
Official Journal of the European Union		C 392

English edition	Information and Notices	Volume 62 19 November 2019

Contents		page
	II Information
	INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES
	European Commission
2019/C 392/01	Non-opposition to a notified concentration (Case M.9548 — Apollo Capital Management/Covivio/Hilton Kilmainham) ( 1 )	1
2019/C 392/02	Non-opposition to a notified concentration (Case M.9570 — Bridgepoint/Latour/Primonial) ( 1 )	2
2019/C 392/03	Non-opposition to a notified concentration (Case M.9509 — Warburg Pincus/CDPQ/Allied Universal) ( 1 )	3

	IV Notices
	NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES
	Council
2019/C 392/04	Notice for the attention of the persons subject to the restrictive measures provided for in Council Decision 2011/72/CFSP and Council Regulation (EU) No 101/2011 concerning restrictive measures directed against certain persons, entities and bodies in view of the situation in Tunisia	4
2019/C 392/05	Notice for the attention of the data subjects to whom the restrictive measures provided for in Council Decision 2011/72/CFSP and Council Regulation (EU) No 101/2011 concerning restrictive measures directed against certain persons, entities and bodies in view of the situation in Tunisia apply	5
	European Commission
2019/C 392/06	Euro exchange rates — 18 November 2019	6
	Court of Auditors
2019/C 392/07	Special Report No 21/2019 Addressing antimicrobial resistance: progress in the animal sector, but this health threat remains a challenge for the EU	7
2019/C 392/08	Special Report No 24/2019 Asylum, relocation and return of migrants: Time to step up action to address disparities between objectives and results	8

	V Announcements
	PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY
	European Commission
2019/C 392/09	Prior notification of a concentration (Case M.9639 — CDC/EDF/Dalkia Investissement) Candidate case for simplified procedure ( 1 )	9
2019/C 392/10	Prior notification of a concentration (Case M.9343 — Hyundai Heavy Industries/Daewoo Shipbuilding & Marine Engineering) ( 1 )	11
2019/C 392/11	Prior notification of a concentration (Case M.9461 — AbbVie/Allergan) ( 1 )	12